Designed to accelerate pre-clinical genomic research and drug discovery for the benefit of patients, the team behind the global genomic data marketplace has grown by nearly 50% in the past year.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
Helix has successfully closed a $200 million financing round, and has revealed that it plans to expand its personal genomics marketplace to accelerate consumer adoption of genomics.
Shares in Celgene, one of biotech’s most successful companies, has dropped 9% following a drug refusal from the Food and Drug Administration.
AstraZeneca has made the decision to push six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases.
U.S. drugmaker Gilead Sciences has announced that it will use Sangamo Therapeutics gene-editing technology to develop cancer treatments in a deal worth potentially $3 billion to Sangamo.
AstraZeneca has secured approval for one of its key new lung cancer drugs, cementing the medicine’s potential to become a blockbuster treatment.
Novartis is gearing up to auction its U.S. generic pill business, a unit that has struggled amid fierce competition, a move pointing to the idea that biosimilars will be the end of ‘big pharma’.
Roche has announced that it intends to purchase the rest of the U.S. cancer data company Flatiron Health for $1.9 billion to speed development of cancer medicines and support its efforts to price them based on how well they work.